Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions

Peptides

Volumn 21, Issue 1, 2000, Pages 49-57

  Haskell Luevano, Carrie ^a   Lim, Sejin ^b   Yuan, Wei ^b   Cone, Roger D ^a   Hruby, Victor J ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b University of Arizona   (United States)

Author keywords

MSH; Melanocortin antagonists; Melanotropin; MTII; SHU9119

Indexed keywords

MELANOCORTIN; MELANOCORTIN RECEPTOR; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; ENERGY BALANCE; EXOCRINE GLAND; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ALPHA-MSH; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; HUMANS; MELANOCYTE-STIMULATING HORMONES; MICE; RECEPTOR, MELANOCORTIN, TYPE 3; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, CORTICOTROPIN; RECEPTORS, MELANOCORTIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033998015     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00167-9     Document Type: Article

References (46)

1. Adan R.A.H., Oosterom J., Ludvigsdottir G., Brakkee J.H., Burbach J.P.H., Gispen W.H. Identification of antagonists for melanocortin MC3, MC4, and MC5 receptors. Eur J Pharmacol Mol Pharmacol. 269:1994;331-337.
2. Al-Obeidi F., Castrucci A.M., Hadley M.E., Hruby V.J. Potent and prolonged acting cyclic lactam analogues of α-melanotropin design based on molecular dynamics. J Med Chem. 32:1989;2555-2561.
3. Castro B, Dormoy JR, Evin G, Seive C. Tetrahedron Lett 1975;14:1219-22.
4. Castrucci A.M.L., Hadley M.E., Sawyer T.K., Wilkes B.C., Al-Obeidi F., Staples D.J., DeVaux A.E., Dym O., Hintz M.F., Riehm J., Rao K.R., Hruby V.J. α-Melanotropin. The minimal active sequence in the lizard skin bioassay. Gen Comp Endocrinol. 73:1989;157-163.
5. Chen W., Kelly M.A., Opitz-Araya X., Thomas R.E., Low M.J., Cone R.D. Exocrine gland dysfunction in MC5-R deficient mice evidence for coordinated regulation Oo exocrine gland functions by melanocortin peptides . Cell. 91:1997;789-798.
6. Chen W., Shields T.S., Stork P.J.S., Cone R.D. A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. Anal Biochem. 226:1995;349-354.
7. De Wied D., Croiset G. Stress modulation of learning and memory processes. Methods Achiev Exp Pathol. 15:1991;167-199.
8. De Wied D., Jolles J. Neuropeptides derived from pro-opiocortin behavioral, physiological, and neurochemical effects . Physiol Rev. 62:1982;976-1059.
9. Desarnaud F., Labbe O., Eggerick D., Vassart G., Parmentier M. Molecular cloning, functional expression, and pharmacological characterization of a mouse melanocortin receptor gene. Biochem J. 299:1994;367-373.
10. Dorr R.T., Lines R., Levine N., Brook C., Xiang L., Hruby V.J., Hadley M.E. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 58:1996;1777-1784.
11. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 385:1997;165-168.
12. Gantz I., Shimoto Y., Konda Y., Miwa H., Dickinson C.J., Yamada T. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun. 200:1994;1214-1220.
13. Griffon N., Mignon V., Facchinetti P., Diaz J., Schwartz J.C., Sokoloff P. Molecular cloning and characterization of the rat fifth melanocortin receptor. Biochem Biophys Res Commun. 200:1994;1007-1014.
14. Hadley ME, Sharma SD, Hruby VJ, Levine N, Dorr RT. Melanotropic peptides for therapeutic and cosmetic tanning of the skin. In: Hubert V, Eberle AN, editors. New York Academy of Sciences: 1993: p.424-39.
15. Haskell-Luevano C. In vitro mutagenesis studies of melanocortin receptor coupling and ligand binding. In: Cone RD, editor. The melanocortin receptors. New Jersey: Humana Press Inc., in press.
16. Haskell-Luevano C., Boteju L.W., Miwa H., Dickinson C., Gantz I., Yamada T., Hadley M.E., Hruby V.J. Topographical modifications of melanotropin peptide analogues with β-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. J Med Chem. 38:1995;4720-4729.
17. Haskell-Luevano C., Hendrata S., North C., Sawyer T.K., Hadley M.E., Hruby V.J., Dickinson C., Gantz I. Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 40:1997;2133-2139.
18. Haskell-Luevano C., Sawyer T.K., Hendrata S., North C., Panahinia L., Stum M., Staples D.J., Castrucci A.M., Hadley M.E., Hruby V.J. Truncation studies of α-melanotropin peptides identifies tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides. 17:1996;995-1002.
19. Haskell-Luevano C., Sawyer T.K., Trumpp-Kallmeyer S., Bikker J., Humblet C., Gantz I., Hruby V.J. Three-dimensional molecular models of the hMC1R melanocortin receptor complexes with melanotropin peptide agonists . Drug Des Deliv. 14:1996;197-211.
20. Hruby V.J., Al-Obeidi F., Sanderson D.G., Smith D.D. Synthesis of cyclic peptides by solid phase methods. Epton R. Innovations and Perspectives in Solid Phase Synthesis. 1989;197-203 SPCC (UK) Ltd, Oxford.
21. 2 with bulky aromatic amino acids at position 7 show high antagonist potency, and selectivity at specific melanocortin receptors. J Med Chem 1995;38:3454-61.
22. Hruby V.J., Wilkes B.C., Cody W.L., Sawyer T.K., Hadley M.E. Melanotropins structural, conformational, and biological considerations in the development of superpotent and superprolonged analogs . Peptide Protein Rev. 3:1984;1-64.
23. Hruby V.J., Wilkes B.C., Hadley M.E., Al-Obeidi F., Sawyer T.K., Staples D.J., DeVaux A., Dym O., Castrucci A.M., Hintz M.F., Riehm J.P., Rao K.R. α-Melanotropin. The minimal active sequence in the frog skin bioassay. J Med Chem. 30:1987;2126-2130.
24. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Smith F.J., Kesterson R.A., Boston B.A., Fang Q., Berkemeir L.R., Gu W., Cone R.D., Campfield L.A., Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 88:1997;131-141.
25. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of tree terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 34:1970;595-598.
26. Kask A., Mutulis F., Muceniece R., Pahkla R., Mutule I., Wikberg J.E., Rago L., Schioth H.B. Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024) evaluation in vitro and in vivo . Endocrinology. 139:1998;5006-5014.
27. Li S.-J., Varga K., Archer P., Hruby V.J., Sharma S.D., Kesterson R.A., Cone R.D., Kunos G. Melanocrotin antagonists define two distinct pathways of cardiovascular control by α- and γ-melanocyte-stimulating hormones. J Neurosci. 16:1996;5182-5188.
28. Lu D., Haskell-Luevano C., Väge D.I., Cone R.D. Functional variants of the MSH receptor (MC1-R), agouti and their effects on mammalian pigmentation. Spiegel A.M. G Proteins, Receptors, and Disease. 1997;231-259 Humana Press Inc, New Jersey.
29. Lu D., Väge D.I., Cone R.D. A ligand-mimetic model for constitutive activation of the melanocortin-1 receptor. Mol Endocrinol. 12:1998;592-604.
30. Lu D., Willard D., Patel I.R., Kadwell S., Overton L., Kost T., Luther M., Chen W., Yowchik R.P., Wilkison W.O., Cone R.D. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature. 371:1994;799-802.
31. Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., Cone R.D. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol. 8:1994;1298-1308.
32. Mountjoy K.G., Robbins L.S., Mortrud M.T., Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science. 257:1992;1248-1251.
33. Ollmann M.M., Wilson B.D., Yang Y.-K., Kerns J.A., Chen Y., Gantz I., Barsh G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 278:1997;135-138.
34. Roselli-Rehfuss L., Mountjoy K.G., Robbins L.S., Mortrud M.T., Low M.J., Tatro J.B., Entwistle M.L., Simerly R.B., Cone R.D. Identification of a receptor for γ melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA. 90:1993;8856-8860.
35. 7] α-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann NY Acad Sci. 680:1993;597-599.
36. Sawyer T.K., Sanfillippo P.J., Hruby V.J., Engel M.H., Heward C.B., Burnett J.B., Hadley M.E. 4-norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone a highly potent α-melanotropin with ultra long biological activity . Proc Natl Acad Sci USA. 77:1980;5754-5758.
37. Schild H.O. pA, a new scale for the measurement of drug antagonism. Br J Pharmacol. 2:1947;189-206.
38. Smith E.M., Hughes T.K., Hashemi F., Stefano G.B. Immunosuppressive effects of corticotropin and melanotropin and their possible significance in human immunodeficiency virus infection. Proc Natl Acad Sci USA. 89:1992;782-786.
39. Stewart J.M., Young J.D. Solid phase peptide synthesis. 1984;Pierce Chemical Co, Rockford, IL.
40. Suzuki I., Cone R.D., Im S., Nordlund J., Abdel-Malek Z.A. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 137:1996;1627-1633.
41. van der Kraan M., Adan R.A., Entwistle M.L., Gispen W.H., Burbach J.P., Tatro J.B. Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology. 139:1998;2348-2355.
42. Vaudry H., Eberle A.N. The Melanotropic Peptides. 1993;Annals of the New York Academy of Sciences, New York.
43. Walker J.M., Akil H., Watson S.J. Evidence for homologous actions of pro-opiomelanocortin products. Science. 210:1980;1247-1249.
44. 7] melanocyte stimulating hormone with the human melanocortin-1 receptor (melanocyte α-MSH receptor). J Biol Chem. 272:1997;23000-23010.
45. Yang Y.-K., Ollmann M.M., Wilson B.D., Dickinson C., Yamada T.G.S., Gantz I. Effects of recombinant agouti signaling protein on melanocortin action. Mol Endocrinol. 11:1997;274-280.
46. Yang Y.-K., Thompson D.A., Dickinson C.J., Wilken J., Barsh G.S., Kent S.B.H., Gantz I. Characterization of agouti-related protein binding to melanocortin receptors. Mol Endocrinol. 13:1999;148-155.